Does Priority Health Cover GLP-1 for Weight Loss?

In most cases, Priority Health does not cover GLP-1 medications for weight loss. The exclusion applies to MyPriority individual and ACA marketplace plans, and Medicare Advantage plans follow the federal rule that has long kept anti-obesity drugs out of Part D. The one route to coverage runs through employer-sponsored plans whose employer has elected a specialized “Responsible Prescribing” buy-up offered with Virta Health. Michigan Medicaid members face a separate, newly tightened set of rules. Which answer applies to you depends entirely on the plan you hold.

Individual and Marketplace Plans

On MyPriority individual and ACA marketplace plans, GLP-1 drugs prescribed strictly for weight loss are not a covered benefit.1Priority Health. MyPriority GLP-1s Agent FAQs Priority Health has pointed to limited long-term outcome data, side-effect concerns, and a monthly cost it estimates at $1,227 to $1,619 as the reasons.

There is no clinical exception that opens coverage for weight loss alone on these plans. GLP-1s are covered on MyPriority when prescribed for type 2 diabetes, specifically Mounjaro and Trulicity at Tier 2, and only when the member is at least 18, has an A1c between 7% and 9%, and has tried and failed at least two oral diabetes drugs (or insulin) at maximum doses over three continuous months.1Priority Health. MyPriority GLP-1s Agent FAQs For members looking for weight-management support without a drug, Priority Health points to its Wellbeing Hub, Active&Fit Direct, and the Diabetes Prevention Program.

Employer-Sponsored Plans and the Virta Health Program

The only way to get GLP-1 coverage for weight loss through Priority Health is the “Sustainable Weight Loss with Responsible Prescribing” program, launched with Virta Health in May 2025.2Priority Health. Priority Health Partners With Virta Health to Offer Diabetes Remission Weight Loss Solutions It is an optional buy-up that employers can add to their plan, available to both self-funded and fully funded groups. If your employer has not elected it, this door is closed. Members who are not sure should check their plan documents or ask their employer directly.

How the Program Works

Virta uses a nutrition-first model with custom care plans, coaching tied to biomarker data, and 24/7 access to a clinician-led care team.3Priority Health. Member Programs Not every participant is prescribed a GLP-1. When one is prescribed, it must come from a provider in Virta’s Trusted Prescriber Network, not from the member’s regular physician.4Priority Health. New Digital Resources for Type 2 Diabetes and Weight Loss GLP-1 prescriptions written for diabetes are not affected by this and do not have to go through Virta.

The program is built around what Virta calls a “clinically monitored off-ramp”: members are expected to combine medication with nutrition and lifestyle changes and eventually transition off the drug while holding on to the weight loss.5Priority Health. Sustainable Weight Loss With Responsible Prescribing Program Details One consequence matters for members: leaving the program means losing coverage for the GLP-1 that was prescribed through it.

Who Qualifies

You must be on a commercial employer group plan whose employer has added the buy-up, be at least 18, and meet FDA criteria for GLP-1 use: a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity.3Priority Health. Member Programs Access to the Virta platform and coaching is free for eligible members. Virtual appointments with Virta providers are billed under your plan’s regular cost-sharing.5Priority Health. Sustainable Weight Loss With Responsible Prescribing Program Details

Michigan Medicaid Plans

Priority Health runs Medicaid managed care plans in Michigan, and the rules for GLP-1 weight-loss coverage tightened sharply on January 1, 2026. The change came from Michigan’s fiscal year 2026 state budget, which cut $240 million in spending on these drugs.6Michigan Public. Michigan Cuts Off Weight Loss Drugs for Most Medicaid Patients, Saving $240 Million

The affected drugs are Saxenda, Wegovy, Zepbound, and generic liraglutide. To get coverage of any of them for obesity alone, a Medicaid member must now be classified as morbidly obese, have documented failure of every other clinically appropriate weight-loss intervention including the preferred anti-obesity agents on the state formulary, and be seeking the drug specifically to avoid higher-cost bariatric surgery.7Michigan DHHS. Numbered Letter L 25-73 Pharmacy Drug Coverage for Treatment of Obesity Saxenda and Wegovy also moved to non-preferred status, which raises copays from $1 to $3 for some beneficiaries.

Members already approved for a GLP-1 before January 1, 2026, keep coverage through the end of their existing six-month authorization, but any renewal has to meet the new criteria.8Priority Health. Medicaid GLP-1 Coverage Changes Effective Jan 1, 2026 Coverage for GLP-1s prescribed for type 2 diabetes, cardiovascular risk reduction, or severe obstructive sleep apnea is not affected. Prior authorization is required for every indication of Wegovy and Zepbound.

Medicare Advantage Plans

Federal law has kept weight-loss drugs out of Medicare Part D, and Priority Health’s Medicare Advantage plans have followed that rule. A temporary CMS demonstration, the Medicare GLP-1 Bridge, changes that for a limited window: it runs from July 1, 2026, through December 31, 2027, and covers Wegovy (injections and tablets), Zepbound (KwikPen only), and Foundayo at a flat $50 monthly copay.9Medicare.gov. Weight Loss Drugs

The Bridge is administered centrally by Humana for CMS, not by Priority Health. Priority Health does not process prior authorizations, claims, or payments under the program.10Priority Health. New CMS Program Expands Medicare Access to GLP-1 Weight Loss Medications Starting July 1 Costs paid through the Bridge do not count toward Part D deductibles or out-of-pocket limits, and the Low Income Subsidy does not apply.

To qualify, a beneficiary must be at least 18, be enrolled in a Medicare Part D plan, and meet one of the BMI thresholds: 35 or higher, 30 or higher with conditions such as heart failure or chronic kidney disease, or 27 or higher with risks such as prediabetes or a prior heart attack.9Medicare.gov. Weight Loss Drugs The provider must submit a prior authorization certifying that the prescription is part of a lifestyle program with diet and exercise.11CMS. Medicare GLP-1 Bridge

If a GLP-1 is prescribed for a condition Part D already covers, such as cardiovascular risk reduction or obstructive sleep apnea, it stays with the member’s Priority Health Part D plan instead of going through the Bridge.10Priority Health. New CMS Program Expands Medicare Access to GLP-1 Weight Loss Medications Starting July 1

When a GLP-1 Is Covered for Something Other Than Weight Loss

Across plan types, GLP-1s prescribed for type 2 diabetes are covered subject to the usual formulary rules. Wegovy for cardiovascular risk reduction has its own prior authorization pathway: the prescription has to come from a cardiologist or endocrinologist, and the member must have established atherosclerotic cardiovascular disease (such as a prior heart attack, stroke, or symptomatic peripheral artery disease), a BMI of at least 27, no history of diabetes, an A1c below 6.5%, and must be on guideline-directed therapy including a high-intensity statin and antiplatelet therapy.12Priority Health. Wegovy for Cardiovascular Risk Reduction Prior Authorization Criteria A diagnosis that is really about weight loss will not slip through these pathways; the clinical criteria do the gatekeeping.

If Your Prescription Is Denied

Options depend on your plan. Medicare members can request a coverage determination or formulary exception, and if that is denied, file a Drug Redetermination appeal using the procedures in Chapter 9 of the Evidence of Coverage.13Priority Health. Exceptions and Complaints Priority Health’s Medicare customer care line is 888-389-6648. Members on commercial plans in Michigan can also seek external review through the Department of Insurance and Financial Services under the state’s Patient’s Right to Independent Review Act.

If you end up paying cash, Zepbound’s retail price runs from roughly $499 to over $1,000 per month, and Eli Lilly’s LillyDirect program starts at $299 per month for the lowest dose.14Eli Lilly. Zepbound Pricing Information Commercial members whose plans do not cover the drug may qualify for manufacturer savings of up to $620 per month. Members on Medicare, Medicaid, or any other government program are not eligible for manufacturer savings cards.